Abstract | BACKGROUND: METHODS: RESULTS: At last follow-up, VA showed improvement (compared to baseline) in 11 eyes (55%), deterioration in three eyes (15%), remained completely unchanged in one eye (5%), and showed improvement initially but returned to baseline levels in five eyes (25%). At last follow-up, CME had relapsed or was still present in 10 of the eyes (50%). The remaining eyes showed complete resolution of the CME, without evidence of recurrence during the follow-up time. Mean VA at last follow-up showed statistically significant improvement (p = 0.02) in nonvitrectomized eyes (mean baseline VA: 1.14 +/- 0.58; mean final VA: 0.96 +/- 0.66) compared to the almost unaltered mean visual acuity for vitrectomized eyes (mean baseline VA: 0.76 +/- 0.41; mean final VA: 0.71 +/- 0.48)(p = 0.40, paired samples t-test). Elevation of IOP was transient in all cases and responded well to topical medications, except for one patient who required placement of an Ahmed valve. Preexisting cataract progressed in three of the 15 phakic eyes (20%). One patient developed a retinal detachment and required additional surgery to reattach it. Patients were followed for a mean of 34 weeks (median: 32 weeks; range: 19-56 weeks). CONCLUSIONS: Intravitreal TA may play a role in the treatment of uveitis-related CME. Further controlled studies are necessary to test this hypothesis.
|
Authors | Sofia Androudi, Erik Letko, Margherita Meniconi, Thekla Papadaki, Muna Ahmed, C Stephen Foster |
Journal | Ocular immunology and inflammation
(Ocul Immunol Inflamm)
2005 Apr-Jun
Vol. 13
Issue 2-3
Pg. 205-12
ISSN: 0927-3948 [Print] England |
PMID | 16019680
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Glucocorticoids
- Triamcinolone Acetonide
|
Topics |
- Adult
- Aged
- Female
- Follow-Up Studies
- Glucocorticoids
(administration & dosage)
- Humans
- Injections
- Intraocular Pressure
- Macular Edema
(drug therapy, etiology, physiopathology)
- Male
- Middle Aged
- Retrospective Studies
- Safety
- Treatment Outcome
- Triamcinolone Acetonide
(administration & dosage)
- Uveitis
(complications, drug therapy, physiopathology)
- Visual Acuity
- Vitreous Body
|